Back to School: How biopharma can reboot drug development. Access exclusive analysis here

NICE's Velcade gotcha

Although the U.K.'s NICE has relented to provision of Velcade bortezomib for multiple myeloma patients under its pay-for-performance agreement with Janssen-Cilag Ltd., it has found another way to limit reimbursement for the drug that patient groups say amounts to moving the goalposts.

NICE stuck by its plan to recommend a full course of eight cycles of Velcade only if patients show a complete or partial response after four cycles, with the pharma company rebating payments for patients who fail treatment.

However, the agency

Read the full 816 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE